Transcript 슬라이드 1 - LG Life Science

IR Presentation
for Growth
Slide 1
NEW Run for Growth
This IR Presentation contains forward-looking
statements that involve risks and uncertainties.
The actual results may differ from those we
project and may be affected by business
environment, government regulation and
legislation, financial market movement, etc.
Slide 2
NEW Run for Growth
 LG Life Sciences…
 Products Line-up
 R&D Activities
 Core Values
Slide 3
History & Growth Pathway
Global
Company
Gearing-up
Building-up
2011
NCE Research
Bio Research
2006
2002
1994
Target
1983
Pharmaceutical
NCE Research
business initiated
Stabilizing
Critical mass
operation
Global market
presence
World-class
Mileston
e
Growth
Driver
performance
Bio research
Acquired ANJIN Pharm corp.
First launch of biopharmaceuticals in
Korea
(Interferon, hGH)
Strategic alliance
Zanidip, Eutropin
R&D productivity
Global products
Euvax B, Eutropin
Out-licensing
Sales efficiency
Innovative R&D
Factive, out-
Factive, approved
Marketing alliance
licensed to SB
from US FDA
Strategic alliance
with Novartis(Korea)
Caspase inhibitor,
with BioPartners
out-licensed to
Gilead
Slide 4
Business Activities - Domestic
Seoul
 Head Office: Seoul
 R&D Center: Daejeon
Daejeon
 Plants : Iksan (Pharmaceuticals, rBST)
Onsan (API, Agrochemicals)
Onsan
 Sales Offices : 11 major cities
Iksan
 Total Personnel : 1,100 (R&D 30%, Sales 30%
Manufacturing 30%)
Slide 5
Business Activities - Overseas
 LGLSI(India) Personnel : 130
 China Branch Personnel : 3
 Global Alliances
• Euvax B
• Valtropin
• Factive
 Total 25 Products
• Factive
• Insecticide
• Boostin
• Euvax B
• Eutropin
• Espogen
• Factive
• Insecticide
• Infertility
• Euvax B
• Eutropin
• Espogen
• Factive
• Euvax B
• Boostin
• Espogen
• Infertility
• Euvax B
• Factive
• Insecticide
• Boostin
• Espogen
• Others
North
America
EU
Middle (11%)
(7%)
East
(11%)
South
America
(29%)
Africa
(4%)
Asia
(36%)
2007 Overseas Sales
($80M, 36%)
Slide 6
Business Results
YoY
2006
2007
Sales
221.2
256.4
16%
57.3
82.5
44%
8.8
25.6
191%
2.2
16.3
641%
4.0%
10.0%
-
3.8%
19.8%
-
Income Before Tax
9.2
23.1
151%
3.0
11.6
287%
Net income
5.9
18.5
214%
1.8
10.9
506%
Operating income
(%)
07 3Q
QoQ
(Bil KRW)
Annual Results
Quarterly Results
(Bil KRW)
Sales(royalties)
Operating Income
07 4Q
(Bil KRW)
Sales(royalties)
Operating Income
256.4 (24.1)
213.6 (20.2) 213.3 (8.5)
82.5 (20.6)
221.2 (3.4)
64.4 (1.2)
179.0 (20.1)
14.8
2003
30.6
2004
0.4
2005
8.8
2006
25.6
3.0
2007
06 4Q
Slide 7
57.5
(2.0)
59.2 (1.3)
57.3 (0.1)
2.5
4.6
2.2
07 1Q
07 2Q
07 3Q
16.3
07 4Q
NEW Run for Growth
 LG Life Sciences…
 Products Line-up
 R&D Activities
 Core Values
Slide 8
Products Line-up
Ex-product Portfolio
Market & Customer
(Mega-trend)
Euvax B
Zanidip
Eutropin
Aging Society
Others
• Product-centered
approach
Factive
Hyruan
Plus
Income Level
Improvement
In-house
15
L/I
10
Others
Co-Marketing
5
1
’02
Chronic
Disease
Slide
10
Well-being
Slide
11
Preventive
Healthcare
Slide
12
• In-house R&D
interest
New Approach
Number of
products
20
Increased Need
for Preventive
Healthcare
• Undefined TA
(therapeutic area)
Newly Defined
Therapeutic Areas
• Clearly defined
TA(therapeutic area)
• Product line-up based
on newly defined TA
• Market & Customer
friendly
’04 ’06 ‘08 ’10
Slide 9
Chronic Disease
Intended Use
FY 05
FY 06
FY 07
Comments
Zanidip
Hypertension(CCB)
47.0
42.0
25.0
Price review
Xilep XL
Hyperlipidemia
-
4.5
6.5
Launched 2Q 06
(Co)-tareg
Hypertension(ARB)
-
1.0
9.0
Launched 4Q 06
Espogen
Anemia
11.5
13.5
13.5
Hyruanplus
Degenerative arthritis
7.5
19.0
24.5
Total Sales
66.0
80.0
78.5
(Bil KRW)
Cardiovascular
Arthritis
- CCB : Calcium Channel Blocker
- ARB : Angiotensin Ⅱ Receptor Blocker
Slide 10
Well-being
Intended Use
(Bil KRW)
Eutropin
Growth
Infertility
Other
-
Declage
GHD(pediatric)
Daily injection
GHD(adult)
Weekly injection
FY 05
FY 06
FY 07
31.0
35.0
37.0
-
-
3.0
Comments
Launched 1Q 07
Boostin
Milk production
stimulant
11.5
11.0
15.5
Follimon
IVF-M, C
Anovulation,
ART
6.0
8.0
8.0
Follitrope
ART
-
0.5
3.0
Launched 4Q 06
Apetrol
Anorexia, Cachexia
-
-
2.5
Launched 1Q 07
Total Sales
48.5
54.5
69.0
GHD : Growth Hormone Deficiency
IVF-M : HMG (human menopausal gonadotropin)
IVF-C : HCG (human chorionic gonadotropin)
ART : Assistant Reproductive Technology
Slide 11
Preventive Healthcare
Vaccines
(Bil KRW)
Intended Use
FY 05
FY 06
FY 07
Comments
Euvax B
Hepatitis B virus
23.0
20.0
17.5
Combo Vaccines
under development
Influenza
Influenza virus
5.0
4.0
5.0
Diagnostics
(Bil KRW)
Intended Use
FY 05
FY 06
FY 07
Comments
Immune
Diagnostics
Hepatitis B/C,
Malaria, AIDS,
pregnancy, etc.
2.0
3.6
4.2
ELISA,
POCT
Molecular
Diagnostics
Tuberculosis,
Cervical cancer,
etc.
-
-
0.3
real time PCR,
DNA Chip
- ELISA : Enzyme-linked Immunosorbent Assay,
- real time PCR : Polymerase Chain Reaction
- POCT : Point-of-care Testing
Slide 12
API Business
FactiveTM
Quinolone antibiotic for respiratory tract infection
1st US FDA-approved drug in Korea
Indication
- 5-day CAP, AECB, ABS
- Excellent efficacy, better patient compliance
Globalization
- US : Launched in Sep. 2004 (Oscient)
- Mexico (Pfizer), Canada (Abbott), EU (Menarini) : Sub-licensed by Oscient
- Russia, South Africa, China, Brazil, Turkey, Middle East, etc. : Launching
CMO Business
Intermediate
(Bil KRW)
Finished Product
AQP
MucostaTM
CBT
PletaalTM
(Rebamipide)
(Cilostazol)
- CAP : Community Acquired Pneumonia,
- ABS : Acute Bacterial Sinusitis,
Intended Use
FY 05
FY 06
FY 07
Gastric ulcer
4.0
6.0
8.5
Antithrombotics
1.0
1.2
1.5
- AECB : Acute Exacerbations of Chronic Bronchitis
- CMO : Contract Manufacturing Organization
Slide 13
Comments
-
NEW Run for Growth
 LG Life Sciences…
 Products Line-up
 R&D Activities
 Core Values
Slide 14
Enhancing R&D productivity
Focused R&D (Outside-In)
Risk Management (Open Innovation)
• Growth
Well-being
• Anti-aging
 Value Creation
Competitiveness
• Infertility
Global Pharma
• Obesity
Chronic
Disease
Market &
Customer
(Mega-trend)
• Cardiovascular
• Diabetes
• Liver disease
• Degenerative
Alliance /
Outsourcing
Preventive
Healthcare
Cost
• Combo-vaccine
• Diagnostics
Target
arthritis
Slide 15
Out-licensing /
Co-development
Candidate,
Pre/PhaseⅠ
PhaseⅡ/Ⅲ,
Approval
R&D Pipeline – New Chemical Entities
Project
Partner
Target
Intended Use
Status
HBV
-
ROW/KR
HBV
PhaseⅡ
Caspase
Gilead
(GS9450)
Worldwide
Liver
Disease
PhaseⅡ
DPP-Ⅳ
-
KR
Diabetes
PhaseⅡ
Alliance
Takeda
Worldwide
Obesity
Discovery
Worldwide
CVS
Discovery
Alliance
Pasteur
(KR)
- HBV : Hepatitis B Virus
- DPP-IV : Dipeptidyl Peptidase IV
- ROW : Rest Of The World
Slide 16
Comments
• Innovative drug
• Januvia (Merck)
• Galvus (Novartis)
• Milestones, Research fund
• Takeda: CT, Commercialization
• Cost Sharing
R&D Pipeline – Biologics
Project
Partner
Target
BioPartners
EU
SR-hGH
Intended Use
Status
Comments
• Co-development
Pediatric/Adult
(Weekly)
PhaseⅢ
-
US
Follitrope
-
ROW/KR
Anovulation
PhaseⅢ
• Expanding claims
EPO
-
ROW/KR
Anemia
PhaseⅢ
• Bio-reactor
SR-IFNα
-
KR
HCV
PhaseⅡ
Facial
augmentation,
Arthritis
Preclinical
HA Derivatives
-
KR
DTaP-HepB
Kaketsuken
ROW/KR
NDA
DTP+ Hepatitis B
DTwP-HepB
-
ROW
• Combo-vaccine
PhaseⅢ
- DTaP : Diphtheria, Tetanus toxoids, acellular(whole cell) Pertussis adsorbed
- ROW : Rest Of The World
Slide 17
NEW Run for Growth
 LG Life Sciences…
 Products Line-up
 R&D Activities
 Core Values
Slide 18
LG Way
LG’s vision is to become the best in its class
Vision
By winning customer’s acclaim
No.1
as a leader in the global market
LG
“Jeong-Do” Management is LG’s unique
“Jeong-Do”
Code of Conduct
code of conduct that governs our management
activities. The English translation of
Management
“Jeong-Do” is “the right way”.
- LG provides equal
Managemnet
Principles
Creating
Respecting
value for
Human
customers
dignity
Slide 19
- LG serves customers
with integrity
- LG strives to build
opportunities for its
employees
- LG rewards its employees
competence through
based on their capabilities
innovation
and performance